Normal saline 0.9

L-Argininine, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, sodium sulfate anhydrous, phosphate buffered saline (10X), and HPLC water were obtained from Fisher Scientific Fair Lawn, NJ. α,α-trehalose dihydrate, polysorbate 80 (Tween® 80, low peroxide), and sodium chloride, USP was purchased from Sigma-Aldrich, St Louis Mo and normal saline 0.9% obtained from Baxter Healthcare Corp., Deerfield, IL.
ELISA analytical kits for bevacizumab (kit #AVA-E-U51) and Ranibizumab (kit #LUC-E-U52) were obtained from United Immunoassay Inc., San Bruno, CA USA. Aflibercept was analyzed using an ELISA procedure as described Celik et al. (25 (link))
Antibodies bevacizumab (Avastin®) 25 mg/ml and ranibizumab (Lucentis®) 10 mg/ml were obtained from Genentech, South San Francisco CA. Intravitreal aflibercept injection (IAI Eylea®) 48.2 mg/ml was obtained from Regeneron, Tarrytown NY. (Note: bulk aflibercept as provided by Regeneron is at 48.2 mg/ml while the common pharmaceutical preparation Eylea® is formulated at 40.0 mg/ml). All other reagents were of analytical or USP purity. Whole globe human donor eye pairs, designated for research, were obtained from Lone Star Lions Eye Bank, Manor, TX, from Lions Eye Bank of Texas/ Baylor College of Medicine, Houston Texas and from TBI Orlando/ Medical Eye Bank of Florida.

L-Argininine, L-(+)-Glutamic Acid, L-Histidine HCl, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate, sodium sulfate anhydrous, polysorbate 20 (Tween^® 20), phosphate buffered saline (10X), and HPLC water were obtained from Fisher Scientific, Fair Lawn, NJ. Pluronic^® F 127, α,α-trehalose dihydrate, polysorbate 80 (Tween^® 80, low peroxide), and sodium chloride, USP was purchased from Sigma-Aldrich, St Louis Mo and normal saline 0.9% obtained from Baxter Healthcare Corp., Deerfield, IL.
ELISA analytical kits for bevacizumab (kit #AVA-E-U51) and ranibizumab (kit #LUC-E-U52) were obtained from United Immunoassay Inc., San Bruno, CA USA. Aflibercept was analyzed using an ELISA procedure as described Celik et al. (20 (link))
Avastin^® (bevacizumab) 25 mg/ml and Lucentis^® (ranibizumab) 10 mg/ml were obtained from Genentech, South San Francisco CA. IAI Eylea^® (intravitreal aflibercept injection) 48.2 mg/ml was obtained from Regeneron, Tarrytown NY. (Note: bulk aflibercept as provided by Regeneron is at 48.2 mg/ml while the common pharmaceutical preparation is formulated at 40.0 mg/ml). All other reagents were of analytical or USP purity.